EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists

Ting Wei, Jiating Ma, Xiaochen Cui, Jiahui Lin, Zhuoqi Zheng, Liu Cheng, Taiying Cui, Xiaoqian Lin, Junjie Zhu, Xuyang Ran, Xiaokun Hong, Luke Johnston und 2 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202507044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Ting Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, SJTU-Yale Joint Center for Biostatistics, National Expe…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Drug Design, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide drugs have revolutionized modern therapeutics, offering novel treatment avenues for various diseases. Nevertheless, low design efficacy, time consumption, and high cost still hinder peptide drug design and discovery. Here, an efficient approach that integrates deep learning‐based protein design with functional screening is presented, enabling the rapid design of biotechnologically important peptides with improved stability and efficacy. 10,000 de novo glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are designed, 60 of these satisfied the stability, efficacy, and diversity criteria in the virtual functional screening. In vitro validations reveal a 52% success rate, and in vivo experiments demonstrate that two lead GLP‐1RAs (D13 and D41) exhibit extended half‐lives, approximately three times longer than that of Semaglutide. In diabetic mouse models, candidate D13 results in significantly lower blood glucose levels than Semaglutide. In the obesity mouse model, D13 induces weight loss efficacy comparable to that of Semaglutide. The AI‐driven peptide design pipeline—which integrates protein design, functional screening, and experimental validation—reduces the number of iterations required to find novel peptide candidates. The entire process, from design to screening, can be completed in a single cycle within two weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDrug DesignHypoglycemic AgentsAnimalsMiceHumansGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorDisease Models, AnimalDiabetes Mellitus, ExperimentalDeep LearningObesityBlood GlucoseGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1RAsSemaglutidedeep learningprotein design

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorBlood GlucoseGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, SJTU-Yale Joint Center for Biostatistics, National Experimental Teaching Center for Life Sciences and Biotechnology, School o…
  • Intelligent Medicine Original Medical Technology (Shanghai) Co., Ltd., Shanghai, 200240, China.
  • College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350116, China.
  • School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

ORCID-Profile: Haifeng Chen

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Science and Technology Commission
  • Medical Engineering Cross Fund of Shanghai Jiao Tong University

Zitieren

APA

Wei, T., Ma, J., Cui, X., Lin, J., Zheng, Z., Cheng, L., Cui, T., Lin, X., Zhu, J., Ran, X., Hong, X., Johnston, L., Yu, Z., & Chen, H. (2025). AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists. Advanced Science. https://doi.org/10.1002/advs.202507044

Vancouver

Wei T, Ma J, Cui X, Lin J, Zheng Z, Cheng L, et al. AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists. Advanced Science. 2025. doi:10.1002/advs.202507044

BibTeX
@article{Wei2025,
  author = {Wei, Ting and Ma, Jiating and Cui, Xiaochen and Lin, Jiahui and Zheng, Zhuoqi and Cheng, Liu and Cui, Taiying and Lin, Xiaoqian and Zhu, Junjie and Ran, Xuyang and Hong, Xiaokun and Johnston, Luke and Yu, Zhangsheng and Chen, Haifeng},
  title = {AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202507044}
}
Kostenlos starten →